A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

Authors

Elena Garralda

Elena Garralda

Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain

Elena Garralda , Ammar Sukari , Nehal J. Lakhani , Amita Patnaik , Yanyan Lou , Seock-Ah Im , Talia Golan , Ravit Geva , Martin Wermke , Maria De Miguel , John Palcza , Sujata Jha , Marya F. Chaney , Jane Anne Healy , Gerald Steven Falchook

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02720068

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3584)

DOI

10.1200/JCO.2021.39.15_suppl.3584

Abstract #

3584

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.

Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.

First Author: Sun Young Rha

First Author: Laura Quan Man Chow

Poster

2019 ASCO Annual Meeting

Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.

Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.

First Author: Nitya Prabhakar Raj